Pharmaceutical Industry Residency Program (PIRP)

The Pharmaceutical Industry Residency Program, formerly named the Industrial Pharmacy Residency Program, is administered by the Leslie Dan Faculty of Pharmacy, University of Toronto, in cooperation with participating Pharmaceutical Companies as listed below. These one or two year specialty residencies develop critical knowledge and skills and provide experience within the stated functional area. This is a national educational residency program for graduates from a recognized Pharmacy degree program; it is not an application for a position with a pharmaceutical company.

Pharmaceutical Industry Residency Program (PIRP) Information Night

A virtual information session was held on Wednesday August 27, 2025, 6:00 - 7:30 PM EST, Online via Zoom to provide an opportunity to learn more about the PIRP and the application process. 

Certification

Over the last few years, many residents and company supervisors have communicated a desire to formally certify the program and we are excited to announce that we have successfully achieved program certification through the Leslie Dan Faculty of Pharmacy, University of Toronto.

Current residents are eligible for the certificate provided they complete the requirements outlined in the terms of reference.

The Leslie Dan Faculty of Pharmacy will continue to support PIRP’s ability to provide high, quality, experiential learning through:

  • Skills and educational webinars and exposure to pharmaceutical industry experts
  • Resume and interview skills workshops
  • Opportunity to network with PIRP residents and pharmaceutical industry professionals
  • Participation in a new mentoring program with a PIRP graduate
  • Collaboration with and guidance from University of Toronto faculty liaisons
  • Coordination to address issues and ensure program requirements are met

PIRP Fees 

To help fund this program, starting in the 2025-26 cycle the program fees are as follows: 
Pharmaceutical company fees based on the number of residency positions offered: 

Positions #1 to #3 

$5,000 per position then 

Positions #4 to #10 

$3,000 per position then 

All positions >10 

$2,000 per position  

Applicant and resident non-refundable fees: 

  • $250 at application (Due September) 
  • $2250 once successfully matched with a company (Due August) 
  • $2500 payable three months after residency employment starts (Due November) 

Applications Process - Opened on Tuesday, September 3, 2025 at 5:00 PM ET | Closed on October 1, 2025 at 5:00 PM ET

Applications are now invited for Residencies starting Summer 2026. To apply:  

  • If you are a current U of T student (PharmD and PFP students who are graduating in Summer next year): Please click here where you will login with your UTORID to access the application form and process. 

  • If you are a graduated U of T student or a non U of T student: please click here for a login. (This may take 3-5 business days so please do as soon as possible). Once your account has been activated, you can login here. Please note that you will not receive an email confirmation once the account has been created and will have to manually check by logging in. 

In the interim, you may prepare to upload the following as part of the application: 

  1. Applicant Contact Information 
  2. University Transcripts from Pharmacy program (in PDF format; unofficial copy accepted – verification may be required) 
  3. Resume or CV 
  4. Reference form (listing contact information of two referees) (click here

Once you have access to CLNx (the application system), please use this guideline to navigate the application process on CLNx. 

Important Note about Application Timeline: 

  • Applications to the PIRP Program will be accepted until Wednesday, October 1, 2025 at 5:00pm ET.  Applications will be reviewed and approved on a rolling basis; selected candidates will be notified.
  • Approved applicants will then have until Monday, October 20, 2025 at 5:00pm ET to finalize their selection of positions. We recommend initiating your application through the CLN “here” link above as soon as possible. 
  • Residency matching results from individual companies will be communicated to successful applicants starting on February 27, 2026 – March 27, 2026, and no longer align with the Hospital Residency Program timelines. 

If you have any questions about the application process, please contact: pharm.residency@utoronto.ca

Key Dates for 2026-27 Residency Application Cycle 

Deadline for Applications 

PIRP program applications: October 1, 2025

Job applications: October 20, 2025 (only approved candidates) 

Applications Shared with Companies November 7, 2025
Interviews November 24, 2025 to February 6, 2026
Company and Applicant Rankings Due February 6, 2026
First Round Matches Released February 27, 2026
Final Round Matches Released March 27, 2026

The Product Development Regulatory and Annual Product Quality Review residencies with Roche, and the residencies with AstraZeneca will be 24 months in length. Please review the updated Terms of Reference document for more information.

2026-2027 Residency Program Participating Companies & Specialties 
  1. Abbvie: Market Access, Immunology and Oncology 
  2. AmgenMedical Information and Medical Affairs | Value, Market Access & Policy
  3. Alexion AstraZeneca: Global Medical Information and Medical Review
  4. AstraZenecaGlobal Clinical Development, Oncology | Market Access 
  5. Bayer: Medical Affairs, Oncology | Market Access
  6. BioGen: Market Access, Rare Disease
  7. Boehringer Ingelheim: Medical Affairs, Oncology and Mental Health | Medical Affairs, Inflammation  
  8. Eisai: Medical Affairs, Oncology and Neurology 
  9. Gilead: Medical Affairs, HIV and Oncology
  10. Lilly: Medical Affairs, Medical Information | Medical Affairs, Oncology | Market Access, Pricing and Reimbursement 
  11. Sanofi: Medical Affairs, Oncology | Medical Affairs, Rare Diseases | Medical Affairs, Immunology | Medical Affairs, Dermatology | Medical Affairs, Respirology | Medical Affairs, Gastrointestinal and Nasal Polyps | Medical Affairs Operations and Transformation | Medical Affairs, Vaccines | Medical Affairs, General Medicine | Market Access, Dupixent | Market Access, General Medicine | Market Access, Oncology and Rare Diseases 
  12. TakedaMedical Affairs, Oncology
  13. MedisonMedical Affairs

Download the PIRP Table of Positions 2026-27 below for more information 

News